LESI Pop-Up Courses Series

The COVID-19 Patent Waiver

October 7, 2021

LESI Pop-Up Classes: Popping up near you...via zoom!
Part 1: Panel Discussion (45 minutes)

- **Welcome** (Dana Colaruli, Peter Ling)
- **Introduction of the Topic** (Julie Barnes-Weise)
- **Introductory Remarks by each speaker** (5 minutes max)
- **General discussion led by Julie** (All)

Part 2: Break-out sessions (45 minutes)

- **Session 1: Will the Waiver Help?**
  Is the waiver worth it also when considering its downsides? Are there better/faster/cheaper solutions that achieve the same goal? Is the waiver based on misconceptions about patents?

- **Session 2: The TRIPS-Agreement is waived – The Day After**
  What would the consequences of a TRIPS-Waiver for various stakeholders be? What further steps would be needed to deploy vaccines and COVID-drugs globally once the TRIPS-Agreement is waived?

- **Session 3: The TRIPS-Agreement is not waived – The Day After**
  If the TRIPS Council does not reach consensus, what else could be done to ensure a fair and swift distribution of vaccines and COVID-related drugs? Can licensing (including compulsory licensing) help? What are the main licensing challenges with respect to COVID-vaccines?
Part 2: Break-out sessions (45 minutes)

- **Session 1: Will the Waiver Help?**
  Is the waiver worth it also when considering its downsides? Are there better/faster/cheaper solutions that achieve the same goal? Is the waiver based on misconceptions about patents?

- **Session 2: The TRIPS-Agreement is waived – The Day After**
  What would the consequences of a TRIPS-Waiver for various stakeholders be? What further steps would be needed to deploy vaccines and COVID-drugs globally once the TRIPS-Agreement is waived?

- **Session 3: The TRIPS-Agreement is not waived – The Day After**
  If the TRIPS Council does not reach consensus, what else could be done to ensure a fair and swift distribution of vaccines and COVID-related drugs? Can licensing (including compulsory licensing) help? What are the main licensing challenges with respect to COVID-vaccines?
Who is LESI?

The Licensing Executives Society International (LESI) is an umbrella association of 33 national and regional Member Societies in more than 90 countries serving more than 6500 individuals.

- A global network of businesses and professionals for 50 years
- 33 member societies in more than 90 countries
- Creating, protecting, and commercializing innovation, and managing and monetizing IP
- Business leaders, IP managers, licensing executives, financiers, licensing companies, brokers
- Experts in law, valuation, protection, transfer, and enforcement of IP
- Advancing the business of intellectual property